^
    Back
    Association details:
    Biomarker:PLK1 overexpression
    Cancer:Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Sci Signal
    Title:

    The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET

    Published date:
    10/04/2022
    Excerpt:
    Combining the MAPK pathway inhibitor trametinib with the RET inhibitor pralsetinib (both of which are clinically approved for some lung cancers) induced tumor regression and prolonged survival in a mouse model of lung cancer with high PLK1 abundance.
    DOI:
    10.1126/scisignal.abj400